All PlansCoverageMedium impact
Hematopoietic Cell Transplantation for Waldenstrom Macroglobulinemia (CPB 0833, reviewed 2025-12-09)
Aetna·Hematology, Oncology, Transplant Surgery·Medical Policy
Effective date
Dec 9, 2025
We identified it
Aug 17, 2026
Summary
Aetna CPB 0833 updates coverage for hematopoietic cell transplantation (HCT) in Waldenstrom macroglobulinemia: autologous HCT is medically necessary for chemo-sensitive salvage treatment, while allogeneic HCT remains experimental/investigational. Billing teams must ensure claims for autologous procedures include required selection criteria documentation, while rejecting allogeneic HCT claims as non-covered.
Action Required
By December 9, 2025: (1) Billing team must update system edits to COVER CPT 38232 (autologous bone marrow harvesting) and CPT 38241 (autologous stem cell transplantation) when ICD-10 diagnosis is C88.00 or C88.01 AND documentation confirms chemo-sensitive disease and salvage treatment indication. (2) Configure system to DENY CPT 38230 (allogeneic harvesting) and CPT 38240 (allogeneic transplantation) for Waldenstrom macroglobulinemia (C88.00, C88.01) with denial reason 'Experimental/Investigational—not covered by plan.' (3) Ensure HCPCS S2150 billing includes prior authorization requirement with documentation of chemo-sensitivity status. (4) Update claim submission templates to alert providers that allogeneic HCT requires prior auth and will likely be denied as experimental. (5) Train billing and authorization staff on the distinction between covered autologous and non-covered allogeneic procedures. Failure to implement restrictions will result in claim denials on appeal and potential overpayment recovery.